Induced protein degradation: an emerging drug discovery paradigm

Lai, Ashton C., Crews, Craig M.·2017·Nature Reviews Drug Discovery
DOI 10.1038/nrd.2016.211

Cites (219)

Items 201–219 of 219

  1. Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograft
    Steven P. Govek, Johnny Y. Nagasawa, Karensa L. Douglas, Andiliy G. Lai, Mehmet Kahraman, Céline Bonnefous, Anna M. Aparicio, Beatrice D. Darimont, Katherine L. Grillot, James D. Joseph et al. · 2015 · Bioorganic & Medicinal Chemistry Letters
  2. Small-molecule androgen receptor downregulators as an approach to treatment of advanced prostate cancer
    Robert Hart Bradbury, Neil J. Hales, Alfred A. Rabow, Graeme E. Walker, David G. Acton, David M. Andrews, Peter G. Ballard, Nigel A.N. Brooks, Nicola Colclough, Alan Girdwood et al. · 2011 · Bioorganic & Medicinal Chemistry Letters
  3. RNA-based therapies
    Irena Melnikova · 2007 · Nature Reviews Drug Discovery
  4. Degradation of Akt using protein-catalyzed capture agents
    Ryan K. Henning, Joseph O. Varghese, Samir Das, Arundhati Nag, Grace Y. Tang, Kevin Tang, Alexander M. Sutherland, James R. Heath · 2016 · Journal of Peptide Science
  5. Nanotechnology for In vivo Targeted siRNA Delivery
    James E. Dahlman, Kevin J. Kauffman, Róbert Langer, Daniel G. Anderson · 2014 · Advances in genetics
  6. Erratum: RNA-based therapies
    Irena Melnikova · 2008 · Nature Reviews Drug Discovery
  7. Discontinued drugs in 2012: oncology drugs
    Robert J. Williams · 2013 · Expert Opinion on Investigational Drugs
  8. Ubiquilin-mediated Small Molecule Inhibition of Mammalian Target of Rapamycin Complex 1 (mTORC1) Signaling
    Rory Coffey, Yuntao Shi, Marcus J. C. Long, Michael T. Marr, Lizbeth Hedstrom · 2016 · Journal of Biological Chemistry
  9. Fulvestrant: Pharmacologic Profile Versus Existing Endocrine Agents for the Treatment of Breast Cancer
    Aman U. Buzdar, John F.R. Robertson · 2006 · Annals of Pharmacotherapy
  10. Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour
    Andrew J. Wagner, Mark Agulnik, Michael Charles Heinrich et al. · 2016 · European Journal of Cancer
  11. Distinct transcriptional responses elicited by unfolded nuclear or cytoplasmic protein in mammalian cells
    Yusuke Miyazaki, Ling‐Chun Chen, Bernard W. Chu, Tomek Swigut, Thomas J. Wandless · 2015 · eLife
  12. Characterization of a New Class of Androgen Receptor Antagonists with Potential Therapeutic Application in Advanced Prostate Cancer
    Huifang Li, Mohamed D.H. Hassona, Nathan A. Lack, Peter Axerio-Cilies, Eric Leblanc, Peyman Tavassoli, Natalia Kanaan, Kate Frewin, Kriti Singh, Hans H. Adomat et al. · 2013 · Molecular Cancer Therapeutics
  13. Immunomodulating Drugs in Myelodysplastic Syndromes
    Lionel Adès, Pierre Fenaux · 2011 · Hematology
  14. A Generic Platform for Cellular Screening Against Ubiquitin Ligases
    Timurs Maculins, Nikki Carter, Thierry Dorval, Kevin Hudson, J. Willem M. Nissink, Ronald T. Hay, Husam A.J. Alwan · 2016 · Scientific Reports
  15. Drug developers delve into the cell's trash-disposal machinery
    Kelly Rae Chi · 2016 · Nature Reviews Drug Discovery
  16. Biogen Idec restructures, sharpens neurology focus
    Peter C. Mitchell · 2011 · Nature Biotechnology
  17. Nature Biotechnology's academic spinouts of 2013
    Aaron J. Bouchie, Malorye Allison, Sarah Webb, Laura DeFrancesco · 2014 · Nature Biotechnology
  18. Antisense battles small molecule for slice of rare lipid disorder market
    Gunjan Sinha · 2013 · Nature Biotechnology
  19. PROTAC the protein
    Kai-Jye Lou · 2012 · Science-Business eXchange